Oxford Biomedica Performance Overview
Oxford Biomedica PLC (ticker OXB.L) closed the trading session on Thursday, 22 September 2026, at GBX 524.95, up 1.15 % from the previous close. The share price is based on transactions across the London Stock Exchange and other major exchanges.
- Current trading price: GBX 524.95
- Shares outstanding: 1.2 million
- Market capitalization: GBX 851.4 million
- Volume traded in the last 24 hours: GBX 93.9 million
- Price change since last month‑end: +6.9 %
- 200‑day simple moving average: GBX 614.45
- 52‑week high: GBX 962 (16 January 2026)
- 52‑week low: GBX 420 (4 September 2026)
Recent Trading Activity of Related Stocks
| Ticker | 24‑hour change | Current price | Market cap (GBX mn) | P/E ratio |
|---|---|---|---|---|
| TEP.L (Telecom Plus) | –0.78 % | GBX 881 | 925.3 | 8.9 |
| APN.L (Applied Nutrition) | +0.35 % | GBX 291.85 | 967.9 | – |
| RNWH.L (Renew) | +0.96 % | GBX 945 | 1 000 | 16.54 |
| MGAM.L (Morgan Advanced Materials Pl) | –0.56 % | GBX 254 | 981.6 | – |
| AZ9.AX (Azzuro) | –7.14 % | AUD 0.01 | 13.3 | – |
Note: P/E ratios are available only for companies that publish earnings data.
Company Profile
Oxford Biomedica PLC is a biotechnology company headquartered in Oxford, United Kingdom. The company develops gene‑ and cell‑therapy treatments for serious diseases, leveraging its FDA‑approved lentiviral vector delivery platform. The platform supports both in‑vivo and ex‑vivo therapeutic approaches. Oxford Biomedica collaborates with global pharmaceutical and biotechnology partners while developing an internal pipeline of gene and cell therapy candidates. The company is listed on the London Stock Exchange and provides further details on its product development and partnerships at www.oxfordbiomedica.co.uk .
